Supporting our observation of ovarian lineage specificity, CRL4 has been identified as a potential therapeutic target in ovarian cancers,38, 67 and these screening efforts underscore the promise of developing pharmacological inhibitors of E3 ligase complexes for cancer treatment. This evidence concerns the gene IL17RB and cancer.